Dec 18 (Reuters) - MetaVia Inc :
* METAVIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 2A CLINICAL TRIAL OF DA-1241 IN PATIENTS WITH PRESUMED MASH
* DA-1241 VERY WELL TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS
* DA-1241 SHOWS SIGNIFICANT REDUCTION IN ALT LEVELS AT WEEKS 4 AND 8
* DA-1241 100MG SHOWS SIGNIFICANT IMPROVEMENTS IN CAP SCORE AT WEEK 16
* DA-1241 100MG SHOWS SIGNIFICANT REDUCTIONS IN HBA1C AT WEEK 16
* EXPECTS END OF PHASE 2 MEETING WITH FDA IN FIRST HALF OF 2025
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。